profit from every $100 of sales.
$0$100
TG Therapeutics
$64.51-0.08% today
+108.4% in 1 year
1-year low $26.941-year high $65.76
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $21.80 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What TG Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $2.79 million in 2022 to $616 million in 2025, with $447 million of profit last year.
SalesProfit
TG Therapeutics vs. similar companies
TG Therapeutics grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| TG Therapeutics | 21.8× · Fair price | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads TG Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 0 | 7 | 3 | 234 | 329 | 616 | |
| – | 6 | 3 | 220 | 291 | 516 | |
| -274 | -345 | -218 | 21 | 42 | 123 | |
| 6 | -342 | -213 | 26 | 50 | 134 | |
| – | -348 | -224 | 13 | 23 | 447 | |
| -2.42 | -2.63 | -1.46 | 0.09 | 0.15 | 2.77 | |
| – | 88.2% | 90.5% | 94.0% | 88.3% | 83.7% | |
| -179,996.1% | -5,154.3% | -7,839.0% | 8.8% | 12.7% | 20.0% | |
| – | -5,204.1% | -8,036.3% | 5.4% | 7.1% | 72.6% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 626 | 380 | 194 | 330 | 578 | 1,063 |
| Cash | 553 | 299 | 102 | 93 | 180 | 79 |
| Total debt | 42 | 79 | 83 | 111 | 254 | 254 |
| Total liabilities | 106 | 142 | 135 | 169 | 355 | 415 |
| 519 | 237 | 59 | 161 | 222 | 648 | |
| 115 | 132 | 135 | 149 | 160 | 161 | |
| 0.9% | -85.6% | -119.1% | 7.5% | 8.2% | 11.7% | |
| – | -146.8% | -382.0% | 7.9% | 10.5% | 69.0% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -215 | -296 | -176 | -31 | -41 | -25 | |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| -215 | -296 | -176 | -31 | -41 | -25 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | 0 | 0 | 9 | 91 | |
| 80 | 61 | 45 | 38 | 43 | 65 |
Valuation
- 21.8×
- 48.4×
- –
- 15.0×
- 15.8×
- –
- 73.9×
- -0.3%
- 4.6%
- 0.0%
Profitability
- 83.7%
- 20.0%
- 72.6%
- 22.4%
- 12.0%
- -23.5%
- 87.4%
- 30.2%
- 11.1%
- 22.5%
Growth
- +426.7%
- –
- +38.4%
- –
- +6.0%
Financial health
- 1.3×
- 0.39
- 49.3%
- 5.0×
- 4.10
- 5.12
- 0.46
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 21%of 952
Top 23%of 884
Top 41%of 601
Bottom 37%of 987
What analysts expect
- Average price target
- $39.00
- Range
- $39.00 – $39.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.17 | 0.23 | −26.1% |
| Feb 26, 2026 | 0.14 | 0.35 | −60.0% |
| Nov 3, 2025 | 2.43 | 0.24 | +912.5% |
| Aug 4, 2025 | 0.17 | 0.32 | −46.9% |
| May 5, 2025 | 0.03 | 0.18 | −83.3% |
| Mar 3, 2025 | 0.15 | 0.08 | +87.5% |
| Nov 4, 2024 | 0.02 | 0.03 | −33.3% |
| Aug 6, 2024 | 0.04 | -0.05 | +180.0% |
News
Atrium Therapeutics, Inc. reports Q3 resultsSeeking Alpha · Nov 13, 2026Cullinan Therapeutics reports Q3 resultsSeeking Alpha · Nov 10, 2026Enliven Therapeutics GAAP EPS of -$0.36Seeking Alpha · Nov 6, 2026Cognition Therapeutics, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Nov 5, 2026Kymera Therapeutics, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Oct 29, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
48No pass
Philip Fisher
58No pass
Peter Lynch
97Pass
Joel Greenblatt
16No pass
Charlie Munger
46No pass
Terry Smith
38No pass
Questions about TG Therapeutics
Is TG Therapeutics a good stock to buy?
A strong, very profitable business at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the TG Therapeutics AI analysis
What does TG Therapeutics do?
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It is in Biotechnology, based in Morrisville, NC, United States, with 399 employees.
Does TG Therapeutics pay a dividend?
No. TG Therapeutics does not pay a dividend at the moment; in 2025 it returned $91.2 million to shareholders by buying back its own shares.
Is TG Therapeutics stock halal?
Yes. TG Therapeutics passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has TG Therapeutics stock done over the past year?
Up 108.4% over the past twelve months, to $64.51. It traded between $26.94 and $65.76, close to its high.
Who are TG Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with TG Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.